

SCHEDULING STATUS: S3

PROPRIETARY NAME AND DOSAGE FORM:

LOGYNON ED®

Tablets

COMPOSITION:

The 28-day pack (Every-Day pack) contains 21 hormonal tablets, 6 tablets each with levonorgestrel (d-13-ethyl-17 α -ethinyl-17 β -hydroxy-4-gonen-3-one) 0,05 mg and ethinylestradiol (17 α -ethinyl-estra-1,3,5(10)-triene-3,17 β -diol) 0,03 mg, plus 5 tablets each with levonorgestrel 0,075 mg and ethinylestradiol 0,04 mg, plus 10 tablets each with levonorgestrel 0,125 mg and ethinylestradiol 0,03 mg, plus 7 non-hormonal tablets.

Excipients are: calcium carbonate, ferric oxide pigment red, ferric oxide pigment yellow, glycerol 85 %, lactose monohydrate, magnesium stearate, maize starch, montan glycol wax, macrogol 6 000, povidone 25 000, povidone 700 000, sucrose, talc and titanium dioxide

PHARMACOLOGICAL CLASSIFICATION:

A 21.8.2 Progesterones with oestrogens

PHARMACOLOGICAL ACTION:

Pharmacodynamic properties:

This medicine is a low dose triphasic oral contraceptive with oestrogenic and progestogenic peripheral effects.

The contraceptive effect of combined oral contraceptives is based on the interaction of various factors, the most important of which are seen as the inhibition of ovulation and the changes in the cervical secretion.

Pharmacokinetic properties:

- Levonorgestrel:

Absorption:

Orally administered levonorgestrel is rapidly and completely absorbed. Maximum levonorgestrel concentrations in serum of 2,3 ng/ml are reached about 1 hour after start of treatment with LOGYNON ED.

Following single ingestion of 0,125 mg levonorgestrel together with 0,03 mg ethinylestradiol (which represents the combination with the highest levonorgestrel content of the triphasic formulation), peak serum concentrations of 4,3 ng/ml are reached at about 1 hour after single ingestion. Levonorgestrel is almost completely bioavailable after oral administration.

Distribution:

Levonorgestrel is bound to serum albumin and to sex hormone binding globulin (SHBG). Only 1,4 % of the total serum drug concentrations are present as free steroid, 55 % are specifically bound to SHBG and about 44 % are non-specifically bound to albumin. The ethinylestradiol-induced increase in SHBG influences the proportion of levonorgestrel bound to the serum proteins, causing an increase of the SHBG-bound fraction and a decrease of the albumin-bound fraction. The apparent volume of distribution of levonorgestrel is about 128 l after single oral administration of the highest levonorgestrel dose of LOGYNON ED.

Metabolism:

Levonorgestrel is completely metabolised by the known pathways of steroid metabolism. The clearance rate from serum is approximately 1,0 ml/min/kg after single oral administration of the highest levonorgestrel dose of LOGYNON ED.



Elimination:

Levonorgestrel serum levels decrease in two phases. The terminal disposition phase is characterised by a half-life of approximately 22 hours. Levonorgestrel is not excreted in unchanged form. Its metabolites are excreted at a urinary to biliary ratio of about 1:1. The half-life of metabolite excretion is about 1 day.

Steady-state conditions:

Levonorgestrel pharmacokinetics are influenced by SHBG levels, which are increased about twofold during the 21-day treatment period with LOGYNON ED. Following daily ingestion, drug serum levels increase about fourfold, reaching steady-state conditions during the second half of a treatment cycle. At steady-state, the volume of distribution and the clearance rate are reduced to 52 l and 0,5 ml/min/kg, respectively.

- Ethinylestradiol:

Absorption:

Orally administered ethinylestradiol is rapidly and completely absorbed. Peak serum concentrations of about 116 pg/ml are reached within 1,3 hours. During absorption and first liver passage, ethinylestradiol is metabolised extensively, resulting in a mean oral bioavailability of about 45 % with a large interindividual variation of about 20 to 65 %.

Distribution:

Ethinylestradiol is highly but non-specifically bound to serum albumin (approximately 98 %) and induces an increase in the serum concentrations of SHBG. An apparent volume of distribution of about 2,8 to 8,6 l/kg was reported.

Metabolism:

Ethinylestradiol is subject to presystemic conjugation in both the small bowel mucosa and the liver. Ethinylestradiol is primarily metabolised by aromatic hydroxylation, but a wide variety of hydroxylated and methylated metabolites are formed, and these are present as free metabolites and as conjugates with glucuronides and sulphate. The clearance rate was reported to be 2,3 to 7 ml/min/kg.

Elimination:

Ethinylestradiol serum levels decrease in two disposition phases characterised by half-lives of about 1 hour and 10 to 20 hours, respectively. Unchanged drug is not excreted; ethinylestradiol metabolites are excreted at a urinary to biliary ratio of 4:6. The half-life of metabolite excretion is about 1 day.

Steady-state conditions:

According to the variable half-life of the terminal disposition phase from serum and the daily ingestion, steady-state serum levels of ethinylestradiol will be reached after about one week. At the end of treatment, the maximum ethinylestradiol concentration of about 132 pg/ml is reached after about 1,3 hours.

INDICATIONS:

Oral contraception.

CONTRA-INDICATIONS:

LOGYNON ED should not be used in the presence of any of the conditions listed below. Should any of the conditions appear for the first time during LOGYNON ED use, the product should be stopped immediately.

- Presence or a history of venous or arterial thrombotic/thromboembolic events (e.g. deep venous thrombosis, pulmonary embolism, myocardial infarction) or of a cerebrovascular accident.
- Presence or history of thrombosis (e.g. transient ischaemic attack, angina pectoris).
- History of migraine with focal neurological symptoms.
- Diabetes mellitus with vascular involvement.
- The presence of a multiple risk factor(s) for venous or arterial thrombosis (such as e.g. hypertension, a family history of thromboembolic events, prolonged immobilisation – see further risk factors for thromboembolism under “Warnings – Circulatory disorders” below) may also constitute a contra-indication (see “Warnings”).

- Pancreatitis or a history thereof if associated with severe hypertriglyceridaemia.
- Presence or history of hepatic disease, as long as liver function values have not returned to normal.
- Presence or history of liver tumours (benign or malignant).
- Known or suspected sex-steroid influenced malignancies (e.g. of the genital organs or the breasts).
- Undiagnosed vaginal bleeding.
- Known or suspected pregnancy.
- Hypersensitivity to the active substances or to any of the excipients.

WARNINGS:

If any of the conditions/risk factors mentioned below are present, the benefits of LOGYNON ED use should be weighed against the possible risks for each individual woman and discussed with the woman before she decides to start using it. In the event of aggravation, exacerbation or first appearance of any of these conditions or risk factors, the woman should contact her physician. The physician should then decide on whether LOGYNON ED use should be discontinued.

Circulatory disorders:

Epidemiological studies have suggested an association between the use of combined oral contraceptives and an increased risk of arterial and venous thrombotic and thromboembolic diseases such as myocardial infarction, stroke, deep venous thrombosis, and pulmonary embolism.

Venous thromboembolism, manifesting as deep venous thrombosis and/or pulmonary embolism, may occur during the use of all combined oral contraceptives, including LOGYNON ED.

Thrombosis has been reported in other blood vessels, e.g. hepatic, mesenteric, renal, cerebral or retinal veins and arteries, in combined oral contraceptive users.

Symptoms of venous or arterial thrombotic/thromboembolic events or of a cerebrovascular accident can include: unilateral leg pain and/or swelling; sudden severe pain in the chest, whether or not it radiates to the left arm; sudden breathlessness; sudden onset of coughing; any unusual, severe prolonged headache; sudden partial or complete loss of vision; diplopia; slurred speech or aphasia; vertigo; collapse with or without focal seizure; weakness or very marked numbness suddenly affecting one side or one part of the body; motor disturbances; 'acute' abdomen.

The risk of venous or arterial thrombotic/thromboembolic events or of a cerebrovascular accident increases with:

- age;
- smoking (with heavier smoking and increasing age the risk increases further, especially in women over 35 years of age);
- a positive family history (i.e. venous or arterial thromboembolism ever in a sibling or parent at a relatively early age). If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any combined oral contraceptive use;
- obesity (body mass index over 30 kg/m²);
- dyslipoproteinaemia;
- hypertension;
- migraine;
- valvular heart disease;
- atrial fibrillation;
- prolonged immobilisation, major surgery, any surgery to the legs, or major trauma. In these situations it is advisable to discontinue combined oral contraceptive use (in the case of elective surgery at least four weeks in advance) and not to resume until two weeks after complete remobilization;
- puerperium.

The increased risk of thromboembolism in the puerperium must be considered (see "Contra-indications" and "Pregnancy and lactation").

Other medical conditions which have been associated with thrombotic incidents include diabetes mellitus, systemic lupus erythematosus, haemolytic uraemic syndrome, chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis) and sickle cell disease.

The onset of, or increase in frequency or severity of migraine during LOGYNON ED use (which may be prodromal of a cerebrovascular event) may be a reason for immediate discontinuation of LOGYNON ED.



Biochemical factors that may be indicative of hereditary or acquired predisposition for venous or arterial thrombosis include Activated Protein C (APC) resistance, hyperhomocysteinaemia, antithrombin-III deficiency, protein C deficiency, protein S deficiency, antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant).

When considering risk/benefit, the physician should take into account that adequate treatment of a condition may reduce the associated risk of thrombosis and that the risk associated with pregnancy is higher than that associated with low-dose LOGYNON ED.

Tumours:

A significantly increased risk of cervical cancer and breast cancer in long-term users of LOGYNON ED has been reported in epidemiological studies.

A meta-analysis from epidemiological studies reported that there is an increased relative risk of having breast cancer diagnosed in women who are currently using combined oral contraceptives.

Benign liver tumours, and rarely, malignant liver tumours have been reported in users of combined oral contraceptives. In isolated cases these tumours have led to life-threatening intra-abdominal haemorrhages. A hepatic tumour should be considered in the differential diagnosis when severe upper abdominal pain, liver enlargement or signs of intra-abdominal haemorrhage occur in women taking combined oral contraceptives.

Other conditions:

Women with hypertriglyceridaemia, or a family history thereof, may be at an increased risk of pancreatitis when using combined oral contraceptives.

Small increases in blood pressure have been reported in many women taking combined oral contraceptives, clinically relevant increases may occur. If a sustained clinically significant hypertension develops during the use of a combined oral contraceptive, then it is prudent for the physician to withdraw the combined oral contraceptive and treat the hypertension. Where considered appropriate, combined oral contraceptive use may be resumed if normotensive values can be achieved with antihypertensive therapy.

The following conditions have been reported to occur or deteriorate with combined oral contraceptive use: jaundice and/or pruritus related to cholestasis; gallstone formation; porphyria; systemic lupus erythematosus; haemolytic uraemic syndrome; Sydenham's chorea; herpes gestationis; otosclerosis-related hearing loss.

In women with hereditary angioedema exogenous oestrogen may induce or exacerbate symptoms of angioedema.

Acute or chronic disturbances of liver function may necessitate the discontinuation of combined oral contraceptive use until markers of liver function return to normal. Recurrence of cholestatic jaundice which occurred first during pregnancy or previous use of sex steroids necessitates the discontinuation of combined oral contraceptives.

Although combined oral contraceptives such as LOGYNON ED may have an effect on peripheral insulin resistance and glucose tolerance, there is no evidence for a need to alter the therapeutic regimen in diabetics using low dose combined oral contraceptives including LOGYNON ED (containing < 0,05 mg ethinylestradiol). However, diabetic women should be carefully observed while taking LOGYNON ED.

Crohn's disease and ulcerative colitis have been associated with combined oral contraceptive use.

Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation whilst taking combined oral contraceptives.

Respiratory: Asthma may deteriorate in women using LOGYNON ED.

In women with hereditary angioedema, LOGYNON ED may induce or exacerbate symptoms of angioedema.

Plasma concentrations of lamotrigine are decreased by 50 %.

INTERACTIONS:

Interactions between LOGYNON ED and other medicines may lead to breakthrough bleeding and/or contraceptive failure. The following interactions have been reported in the literature:

Hepatic metabolism:

Interactions can occur with medicines that induce microsomal enzymes, which can result in an increased clearance of sex hormones (e.g. phenytoin, barbiturates, primidone, carbamazepine, rifampicin, and possibly also oxcarbazepine, topiramate, felbamate, griseofulvin, products containing St John's Wort) and HIV protease (e.g. ritonavir) and non-nucleoside reverse transcriptase inhibitors (e.g. nevirapine), and combinations of them.

Interference with enterohepatic circulation:

Some clinical reports suggest that enterohepatic circulation of estrogens may decrease when certain antibiotic agents are given, which may reduce ethinylestradiol concentrations (e.g. penicillins, tetracyclines).

Women on treatment with any of these drugs should temporarily use a barrier method in addition to the combined oral contraceptive, or choose another method of contraception. With microsomal enzyme-inducing drugs, the barrier method should be used during the time of concomitant drug administration and for 28 days after their discontinuation. Women on treatment with antibiotics (except rifampicin and griseofulvin) should use the barrier method until 7 days after discontinuation. If the period during which the barrier method is used runs beyond the end of the active tablets in the LOGYNON ED pack, the inactive tablets should be omitted and the next combined oral contraceptive pack should be started.

LOGYNON ED may interfere with the metabolism of other medicines. Accordingly, plasma and tissue concentrations may either increase (e.g. an increase in cyclosporin and benzodiazepines) or decrease (e.g. lamotrigine). **Plasma concentrations of lamotrigine are decreased by 50 %.**

Note: The prescribing information of concomitant medications should be consulted to identify potential interactions.

Laboratory tests:

The use of contraceptive steroids may influence the results of certain laboratory tests, including biochemical parameters of liver, thyroid, adrenal and renal function, plasma levels of (carrier) proteins, e.g. corticosteroid binding globulin and lipid/lipoprotein fractions, parameters of carbohydrate metabolism and parameters of coagulation and fibrinolysis. Changes generally remain within the normal laboratory range.

PREGNANCY AND LACTATION:

LOGYNON ED is contra-indicated during pregnancy. If pregnancy occurs during treatment with LOGYNON ED, further intake should be stopped (see "Contra-indications").

Extensive epidemiological studies have revealed neither an increased risk of birth defects in children born to women who used combined oral contraceptives prior to pregnancy, nor a teratogenic effect when combined oral contraceptives were taken inadvertently during early pregnancy.

Lactation may be influenced by combined oral contraceptives as they may reduce the quantity and change the composition of breast milk. Therefore, the use of combined oral contraceptives should generally not be recommended until the nursing mother has completely weaned her child. Small amounts of the contraceptive steroids and/or their metabolites may be excreted with the milk, but there is no evidence that this adversely affects infant health.

DOSAGE AND DIRECTIONS FOR USE:

Combined oral contraceptives, when taken correctly, have a failure rate of approximately 1 % per year. The failure rate may increase when pills are missed or taken incorrectly.

Medical examination/consultation:

A complete medical history and physical examination should be taken prior to the initiation or reinstatement of combined oral contraceptive use, guided by the “Contra-indications” and “Warnings”, and should be repeated periodically. Periodic medical assessment is also of importance because contra-indications (e.g. a transient ischaemic attack, etc) or risk factors (e.g. a family history of venous or arterial thrombosis) may appear for the first time during the use of a combined oral contraceptive. The frequency and nature of these assessments should be adapted to the individual woman but should generally include special reference to blood pressure, breasts, abdomen and pelvic organs, including cervical cytology and relevant laboratory tests.

How to take LOGYNON ED:

Tablets must be taken in the order directed by the arrows on the pack, every day at about the same time with some liquid as needed. Tablet-taking is continuous. One tablet is to be taken daily for 28 consecutive days. The first tablet should be taken from the red section of the calendar pack by selecting the appropriate tablet for that day of the week (e.g. “MO” for Monday). Each subsequent pack is started the day after the last tablet of the previous pack. Withdrawal bleeding usually starts on 2 to 3 days after starting the inactive tablets and may not have finished before the next pack is started. If a patient starts LOGYNON ED during the latter part of the week, the very first cycle may be slightly shortened.

How to start LOGYNON ED:

7 days of uninterrupted active tablet-taking are required to attain adequate suppression of the hypothalamic-pituitary-ovarian-axis.

No preceding hormonal contraceptive use (in the past month):

Tablet-taking has to start on day 1 of the woman’s natural cycle (ie the first day of her menstrual bleeding). If the woman starts with an inactive tablet on day 1, she should be advised to additionally use a barrier method for the first 14 days of tablet-taking. Starting on days 2 to 5 is allowed, but during the first cycle a barrier method is recommended in addition for the first 14 days of tablet-taking.

Changing from a combined hormonal contraceptive (combined oral contraceptive/COC), vaginal ring, or transdermal patch):

The woman should start with LOGYNON ED preferably on the day after the last active tablet (the last tablet containing the active substances) of her previous combined oral contraceptive, but at the latest on the day following the usual tablet-free or placebo tablet interval of her previous combined oral contraceptive. In case a vaginal ring or transdermal patch has been used, the woman should start using LOGYNON ED preferably on the day of removal, but at the latest when the next application would have been due.

Changing from a progestogen-only method (minipill, injection, implant) or from a progestogen-releasing intrauterine system:

The woman may switch on any day from the minipill (from an implant or the intrauterine system on the day of its removal, from an injectable when the next injection would be due), but should in all of these cases be advised to additionally use a barrier method for the first 14 days of tablet-taking.

Following first trimester abortion:

The woman may start immediately. She should be advised to additionally use a barrier method for the first 14 days of tablet-taking.

Following delivery or second-trimester abortion:

For breastfeeding women see “Pregnancy and lactation”.



Women should be advised to start on day 21 after delivery or second-trimester abortion. When starting later, the woman should be advised to additionally use a barrier method for the first 14 days of tablet-taking. However, if intercourse has already occurred, pregnancy should be excluded before the actual start of combined oral contraceptive use or the woman has to wait for her first menstrual period.

Management of missed tablets:

Missed large white inactive tablets can be disregarded. However, they should be discarded to avoid unintentionally prolonging the inactive tablet phase. The following advice only refers to missed active tablets.

If the user is **less than 12 hours** late in taking any active tablet, contraceptive protection is not reduced. The woman should take the tablet as soon as she remembers and should take further tablets at the usual time.

If she is **more than 12 hours** late in taking any active tablet, contraceptive protection may be reduced. The management of missed tablets can be guided by the following two basic rules:

1. active tablet-taking must never be discontinued for longer than 7 days;
2. 7 days of uninterrupted active tablet-taking are required to attain adequate suppression of the hypothalamic-pituitary-ovarian-axis.

Accordingly, the following advice can be given in daily practice:

First 7 days of active tablet-taking:

The user should take the last missed tablet as soon as she remembers, even if this means taking two tablets at the same time. She then continues to take tablets at her usual time. In addition, a barrier method such as a condom should be used for the next 7 days. If intercourse took place in the preceding 7 days, the possibility of a pregnancy should be considered. The more tablets that are missed and the closer they are to the inactive tablet phase, the higher the risk of a pregnancy.

Second 7 days of active tablet-taking:

The user should take the last missed tablet as soon as she remembers, even if this means taking two tablets at the same time. She then continues to take tablets at her usual time. Provided that the woman has taken her tablets correctly in the 7 days preceding the first missed tablet, there is no need to use extra contraceptive precautions. However, if this is not the case, or if she missed more than 1 tablet, the woman should be advised to use extra precautions for 7 days.

Third 7 days of active tablet-taking:

The risk of reduced reliability is imminent because of the forthcoming inactive tablet phase. However, by adjusting the tablet-intake schedule, reduced contraceptive protection can still be prevented. By adhering to either of the following two options, there is therefore no need to use extra contraceptive precautions, provided that in the 7 days preceding the first missed tablet the woman has taken all tablets correctly. If this is not the case, the woman should be advised to follow the first of these two options, and also to use extra precautions for the next 7 days as well.

1. The user should take the last missed tablet as soon as she remembers, even if this means taking two tablets at the same time. She then continues to take tablets at her usual time until the active tablets are used up, i.e. the last small ochre active tablet on "FR". The 7 inactive tablets must be discarded. The next pack must be started right away with the pale brown active "SA" tablet from the red section. The user is unlikely to have a withdrawal bleed until the end of the active tablets section of the second pack, but she may experience spotting or breakthrough bleeding on active tablet-taking days.
2. The woman may also be advised to discontinue active tablet-taking from the current pack. She should then have a tablet-free interval of up to 7 days, including the days she missed tablets, and subsequently continue with the next pack, starting in the red section with the tablet for the appropriate day of the week, and use extra precautions for the next 14 days.

If the woman missed active tablets and subsequently has no withdrawal bleed in the inactive tablet phase, the possibility of a pregnancy should be considered.

Advice in case of gastrointestinal disturbances:

In the case of severe gastrointestinal disturbances, absorption may not be complete and additional contraceptive measures should be taken.

If vomiting occurs within 3 to 4 hours after active tablet-taking, the advice concerning missed tablets is applicable. If the woman does not want to change her normal tablet-taking schedule, she has to take the extra tablet(s) needed from another pack.

How to delay a period:

A period can be delayed for about 10 days. To delay a period the woman should complete all the small active tablets (pale brown, white and ochre) of the current pack and discard the large white inactive tablets. A new pack must then be started with the first small ochre active tablet marked "WE". The days will not correspond to actual calendar days. One tablet must be taken daily, following the arrows on the pack. After taking the last small ochre active tablet marked "FR" from this second pack, the rest of the pack must be discarded. A third pack should then be started with the large white inactive tablet in the red section marked "TU". The woman's period will usually start in this section. Tablet-taking should then continue as normal. During the extension the woman may experience breakthrough-bleeding or spotting.

Reduced cycle control:

With all combined oral contraceptives such as LOGYNON ED, irregular bleeding (spotting or breakthrough bleeding) may occur, especially during the first months of use. Therefore, the evaluation of any irregular bleeding is only meaningful after an adaptation interval of about three cycles.

If bleeding irregularities persist or occur after previously regular cycles, then non-hormonal causes should be considered and adequate diagnostic measures are indicated to exclude malignancy or pregnancy. These may include curettage.

In some women withdrawal bleeding may not occur during the inactive tablet phase. If LOGYNON ED has been taken according to the directions described in "Dosage and directions for use", it is unlikely that the woman is pregnant. However, if the combined oral contraceptive has not been taken according to these directions prior to the first missed withdrawal bleed or if two withdrawal bleeds are missed, pregnancy must be ruled out before LOGYNON ED is continued.

SIDE EFFECTS AND SPECIAL PRECAUTIONS:

Side effects:

The most serious undesirable effects associated with the use of LOGYNON ED are listed under "Warnings".

Other side effects that have been reported in users of LOGYNON ED but for which the association has been neither confirmed nor refuted are:* (see "Warnings")

System organ class	Common (≥ 1/100)	Uncommon (≥ 1/1000 and < 1/100)	Rare (< 1/1000)
Eye disorders			Contact lens intolerance
Gastrointestinal disorders	Nausea Abdominal pain	Vomiting Diarrhoea	
Immune system disorders			Hypersensitivity
Investigations	Weight increased		Weight decreased
Metabolism and nutrition disorders		Fluid retention	
Nervous system disorders	Headache	Migraine	
Psychiatric disorders	Depressed mood Mood altered	Libido decreased	Libido increased
Reproductive system and breast disorders	Breast pain Breast tenderness	Breast hypertrophy	Vaginal discharge Breast discharge
Skin and subcutaneous tissue disorders		Rash Urticaria	Erythema nodosum Erythema multiforme



* The most appropriate MedDRA term (Version 7.0) to describe a certain adverse reaction is listed. Synonyms or related conditions are not listed, but should be taken into account as well.

In women with hereditary angioedema exogenous oestrogen may induce or exacerbate symptoms of angioedema.

Special precautions:

Women should be advised that LOGYNON ED does not protect against HIV infections (AIDS) and other sexually transmitted diseases.

Reduced efficacy:

The efficacy of combined oral contraceptives may be reduced in the event of e.g. missed active tablets, gastrointestinal disturbances during active tablet-taking (see "Dosage and directions for use"), or concomitant medication (see "Interactions").

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:

There have been no reports of serious deleterious effects from overdose. Symptoms that may occur in case of taking an overdose of active tablets are: nausea; vomiting; and in young girls slight vaginal bleeding. There are no antidotes and further treatment should be symptomatic.

IDENTIFICATION:

6 small pale brown coated hormonal tablets, 5 small white coated hormonal tablets, 10 small ochre coated hormonal tablets, and 7 large white coated non-hormonal tablets.

PRESENTATION:

Cartons with one or three blister calendar packs containing 28 tablets.

STORAGE INSTRUCTIONS:

In original packs at room temperature (at or below 25 °C). Protect from light.
KEEP OUT OF REACH OF CHILDREN.

REGISTRATION NUMBER:

South Africa: N/21.8.2/113
Botswana: B9319920 (S2)
Namibia: 90/21.8.2/013 (S1)
Zimbabwe: 81/21.2.1/1419 (PP10)
N/21.8.2/113

NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION:

Bayer (Pty) Ltd
Reg. No.: 1968/011192/07
27 Wrench Road
ISANDO
1609

DATE OF PUBLICATION OF THIS PACKAGE INSERT:

2 March 2012